AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s latest clinical study, titled ‘Observational, Secondary Data Collection Study to Describe Acalabrutinib Treatment Outcomes in Chronic Lymphocytic Leukemia Patients in Real-life Setting in Romania,’ aims to evaluate the real-world outcomes of acalabrutinib in Romanian patients with chronic lymphocytic leukemia (CLL). The study’s primary objective is to assess the time to treatment discontinuation, while secondary objectives include understanding the reasons for discontinuation, treatment effectiveness, and patient demographics.
The intervention under investigation is acalabrutinib, a drug approved by the European Medicines Agency for CLL treatment. This study is non-interventional and focuses on collecting retrospective data from patients who have been routinely initiated on acalabrutinib.
The study is observational with a cohort model and retrospective time perspective. It involves two cohorts: the first cohort includes patients initiated on acalabrutinib in 2023, and the second cohort includes those from 2024. The study does not involve any masking or allocation, as it is purely observational.
Key dates for this study include its start date on December 13, 2023, with the last update submitted on August 12, 2025. These dates are crucial for tracking the study’s progress and ensuring timely data collection and analysis.
The study’s findings could significantly impact AstraZeneca’s stock performance by providing insights into acalabrutinib’s effectiveness in real-world settings, potentially influencing investor sentiment positively. As the market for CLL treatments is competitive, these outcomes may also affect AstraZeneca’s positioning relative to its competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.